Table 2.
Association of CD206 expression with morphologic and chromosomal abnormalities.
| Variable | AML (Cohort 2) |
||
|---|---|---|---|
| High CD206 (n = 150) |
Low CD206 (n = 150) |
P | |
| FAB classification, n (%) | |||
| M0 | 16 (10.7) | 7 (4.7) | 0.05 |
| M1 | 28 (18.7) | 37 (24.7) | 0.21 |
| M2 | 37 (24.7) | 33 (22.0) | 0.59 |
| M3 | 9 (6.0) | 32 (21.3) | 0.0001 |
| M4 | 46 (30.7) | 24 (16.0) | 0.003 |
| M5 | 8 (5.3) | 15 (10.0) | 0.13 |
| M6 | 2 (1.3) | 1 (0.7) | 1 |
| M7 | 2 (1.3) | 1 (0.7) | 1 |
| Unknown | 2 (1.3) | 0 (0) | 0.50 |
| Cytogenetics, n (%) | |||
| normal | 61 (40.9) | 69 (46.0) | 0.38 |
| t(8;21) | 6 (4.0) | 8 (5.3) | 0.59 |
| inv(16) | 20 (13.4) | 2 (1.3) | < 0.0001 |
| t(15;17) | 8 (5.4) | 30 (20) | 0.0001 |
| Complex |
15 (10.1) |
5 (3.3) |
0.02 |
| AML (Cohort 3)* |
|||
| Variable |
High CD206 (n = 221) |
Low CD206 (n = 222) |
P |
| FAB classification, n (%) | |||
| M0 | 10 (4.5) | 6 (2.7) | 0.30 |
| M1 | 36 (16.3) | 59 (26.6) | 0.008 |
| M2 | 47 (21.3) | 58 (26.1) | 0.23 |
| M3 | 8 (3.6) | 16 (7.2) | 0.10 |
| M4 | 54 (24.4) | 25 (11.3) | < 0.001 |
| M4E | 5 (2.3) | 0 (0) | 0.03 |
| M5 | 55 (24.9) | 49 (22.1) | 0.48 |
| M6 | 4 (1.8) | 2 (0.9) | 0.45 |
| Unknown | 2 (0.9) | 7 (3.2) | 0.09 |
| Cytogenetics, n (%) | |||
| normal | 82 (37.1) | 99 (44.6) | 0.11 |
| t(8;21) | 15 (6.8) | 20 (8.3) | 0.39 |
| inv(16) | 33 (14.9) | 1 (0.5) | < 0.0001 |
| t(15;17) | 6 (2.7) | 15 (6.8) | 0.05 |
| Complex | 6 (2.7) | 7 (3.2) | 0.78 |
Abbreviations: AML, acute myeloid leukemia;
*17 cases of myelodysplastic syndrome (MDS) cases are removed from Cohort 3 (n = 460), leaving 443 cases for analysis.